Literature DB >> 8336947

Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.

S Sarkar1, T D Gilmore.   

Abstract

The vRel oncoprotein of the avian Rev-T retrovirus is a member of the Rel/NF-kappa B family of transcription factors. The highly conserved amino-terminal Rel Homology (RH) domain in these proteins is required for DNA binding, protein-protein interactions and nuclear localization, and many mutations within this domain abolish transformation by vRel. We demonstrate here that overexpression of the vRel RH domain alone is insufficient to induce transformation of chicken spleen cells, indicating that sequences from the nonconserved carboxy terminus are necessary for the vRel transforming function. Therefore, we constructed and assayed several vRel mutants with deletions of carboxy-terminal sequences. These mutant vRel proteins did not transform spleen cells with equal efficiency, even though they were functionally similar by several other criteria. Our results demonstrate that there are two regions (aa 389 to 432 and aa 437 to 503) within the carboxy-terminal half of vRel that are important for transformation: mutant vRel proteins containing the RH domain and one or both of these carboxy-terminal regions can transform at roughly wild-type levels. Analysis of Gal4 fusion proteins containing carboxy-terminal sequences from the vRel mutants indicated that there is a correlation between the ability of these mutant proteins to transform avian spleen cells and their ability to activate transcription. These observations suggest that vRel induces malignant transformation by directly altering gene expression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8336947

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

1.  Role of Nr13 in regulation of programmed cell death in the bursa of Fabricius.

Authors:  R M Lee; G Gillet; J Burnside; S J Thomas; P Neiman
Journal:  Genes Dev       Date:  1999-03-15       Impact factor: 11.361

2.  Interaction of the v-Rel oncoprotein with NF-kappaB and IkappaB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-2 are functional in vitro and in vivo.

Authors:  D W White; G A Pitoc; T D Gilmore
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

3.  AP-1 factors play an important role in transformation induced by the v-rel oncogene.

Authors:  J Kralova; A S Liss; W Bargmann; H R Bose
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

4.  ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein.

Authors:  M You; P T Ku; R Hrdlicková; H R Bose
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

5.  Temperature-sensitive transforming mutants of the v-rel oncogene.

Authors:  D W White; T D Gilmore
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

6.  NF-kappa B p100 is one of the high-molecular-weight proteins complexed with the v-Rel oncoprotein in transformed chicken spleen cells.

Authors:  S Sif; T D Gilmore
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  Heterologous C-terminal sequences disrupt transcriptional activation and oncogenesis by p59v-rel.

Authors:  J A Diehl; M Hannink
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

8.  Interaction of the v-Rel oncoprotein with cellular transcription factor Sp1.

Authors:  S Sif; T D Gilmore
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

9.  Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformation.

Authors:  J Nehyba; R Hrdlicková; E H Humphries
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

10.  Transformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids.

Authors:  J Kralova; J D Schatzle; W Bargmann; H R Bose
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.